Abstract
Achieving rapid healing of chronic wounds is still highly demanded. In the last few decades, exogenous administration of basic fibroblast growth factor (bFGF) in both clinical and preclinical investigations has proven to be therapeutically effective. However, the adverse wound environment (e.g., increased inflammation) deteriorates the functionality of bFGF. Therefore, improvements of the wound “soil” in addition to the use of bFGF is of importance to future clinical success. To address this issue, we designed an injectable host–guest drug delivery system for the controlled release of the hydrophilic bFGF alongside the hydrophobic anti-inflammatory drug, Pinocembrin (PNCB), to promote effective wound repair. The hydrophobic PNCB was first loaded into Pluronic F127 micelles (PNCB@F127) and then threaded onto bFGF-mixed α-cyclodextrin (α-CD) chains to form the host–guest hydrogel (P/bFGF@F127α-CD). The in vitro and in vivo results demonstrated that P/bFGF@F127α-CD could effectively accelerate wound healing by combining the therapeutic effects of both PNCB and bFGF. The results showed the potential of combining anti-inflammatory drugs with growth factors for wound healing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
